P1.13A.01 DeLLphi-306 Trial: A Phase 3 Study of Tarlatamab after Concurrent Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer
Back to course
Pdf Summary
Asset Subtitle
Afshin Dowlati
Meta Tag
Speaker Afshin Dowlati
Topic SCLC & Neuroendocrine Tumors
Keywords
DeLLphi-306 trial
tarlatamab
bispecific T-cell engager
small cell lung cancer
progression-free survival
overall survival
Phase 3 study
DLL3 pathway
Amgen Inc.
ClinicalTrials.gov
Powered By